NODULAR REGENERATIVE HYPERPLASIA

This adverse event was reported 642 times

NODULAR REGENERATIVE HYPERPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ADO-TRASTUZUMAB EMTANSINE 53 0.0063
1 NELFINAVIR MESYLATE 10 0.0048
2 NEVIRAPINE 41 0.0046
3 ZIDOVUDINE 39 0.0038
4 INOTUZUMAB OZOGAMICIN 7 0.0023
5 EFAVIRENZ 23 0.0021
6 LAMIVUDINE 47 0.0019
7 RALTEGRAVIR 9 0.0017
8 MERCAPTOPURINE 29 0.0017
9 ABACAVIR SULFATE 16 0.0016
See all drugs enriched for association with NODULAR REGENERATIVE HYPERPLASIA